#1 Clinical Trials Search in Europe

Kk8123

A groundbreaking clinical trial is underway to evaluate the potential of KK8123, a novel drug designed to treat X-linked Hypophosphatemia (XLH). This first-in-human study aims to assess the safety, tolerability, and effectiveness of KK8123 in adult patients with XLH. The trial consists of multiple phases, including dose escalation and an optional extension period, providing valuable insights into this innovative treatment approach.

Table of Contents

What is KK8123?

KK8123 is a new experimental medication that is currently being studied for the treatment of a rare genetic condition called X-linked Hypophosphatemia (XLH)[1]. This drug is in the early stages of research, and scientists are conducting what’s called a “first-in-human” study. This means that KK8123 is being tested in humans for the first time to understand how it works in the body and whether it’s safe and effective[1].

What condition does KK8123 aim to treat?

KK8123 is being developed to treat X-linked Hypophosphatemia (XLH)[1]. XLH is a rare genetic disorder that affects how the body processes phosphate, an important mineral for bone health. People with XLH have low levels of phosphate in their blood, which can lead to weak and soft bones, bone pain, and other skeletal problems. The “X-linked” part of the name means that the condition is typically passed down from parent to child through the X chromosome, one of the chromosomes that determines a person’s biological sex[1].

Current Clinical Trial

The ongoing study for KK8123 is known as a Phase 1/2 clinical trial[1]. This type of study is designed to:

  • Test the safety of the drug: Researchers carefully monitor participants for any side effects or adverse reactions.
  • Determine the right dose: Different amounts of the drug are tested to find the most effective and safest dose.
  • Understand how the drug works in the body: This includes how it’s absorbed, distributed, and eliminated (pharmacokinetics or PK), and what effects it has (pharmacodynamics or PD).
  • Get early indications of whether the drug is effective: While the main goal is safety, researchers also look for signs that the drug is working as intended.

How is KK8123 administered?

KK8123 is given as a subcutaneous injection[1]. This means the medication is injected just under the skin, similar to how some diabetes medications are given. This method of administration allows the drug to be absorbed slowly into the bloodstream.

Study Design

The clinical trial for KK8123 is divided into two main parts[1]:

  1. Part 1: Dose Escalation Period
    • This part lasts 32 to 44 weeks.
    • Different groups (cohorts) of participants receive increasing doses of KK8123.
    • Cohort 1 receives a low, single dose.
    • Cohort 2 receives a mild dose, given multiple times.
    • Cohort 3 receives a high dose, given multiple times.
    • There’s an optional Cohort 4, also receiving multiple doses.
  2. Part 2: Extension Period
    • This is an optional part that lasts up to 52 weeks.
    • Participants receive multiple doses of KK8123 at the high dose level determined to be safe in Part 1.
This design allows researchers to carefully monitor the effects of KK8123 at different doses and over an extended period.

Safety Monitoring

Throughout the study, participants are closely monitored for any side effects or adverse reactions. This includes[1]:

  • Regular blood tests to check for changes in blood cell counts and chemistry.
  • Monitoring of vital signs like temperature, pulse rate, breathing rate, and blood pressure.
  • Heart monitoring through ECGs, looking at measurements like QT interval (a measure of the heart’s electrical activity).
  • Echocardiograms to check for any changes in heart structure or function.
  • Ultrasounds of the kidneys to check for any changes.
These tests help ensure the safety of participants and provide valuable information about how KK8123 affects the body.

Measures of Effectiveness

While safety is the primary focus of this early-stage trial, researchers are also looking for signs that KK8123 is effective. The main measure of effectiveness is the drug’s impact on serum phosphorus levels[1]. Serum phosphorus refers to the amount of phosphate in the blood. Since XLH causes low phosphate levels, an effective treatment would be expected to increase these levels.

Additionally, researchers are studying how the body processes KK8123. This includes measuring[1]:

  • How much of the drug reaches the bloodstream and how quickly (Cmax and tmax)
  • How long the drug stays in the body (half-life)
  • How the body clears the drug
  • Whether the drug accumulates in the body with multiple doses
This information helps researchers understand how often the drug needs to be given and at what dose to be most effective and safe.

Aspect Details
Drug Name KK8123
Condition Treated X-linked Hypophosphatemia (XLH)
Administration Method Subcutaneous injection
Study Type Phase 1/2, multicenter, open-label, dose-escalation
Study Duration Part 1: Up to 44 weeks, Part 2 (extension): Up to 52 weeks
Primary Outcomes Safety, tolerability, pharmacokinetics, pharmacodynamics, effect on serum phosphorus levels
Secondary Outcomes Anti-drug antibody (ADA) development
Key Measurements TEAEs, blood tests, vital signs, heart function, kidney function, drug concentrations in blood

FAQ

  • What is X-linked Hypophosphatemia (XLH)? X-linked Hypophosphatemia (XLH) is a rare genetic disorder that affects the body's ability to maintain normal phosphate levels in the blood. This condition can lead to bone deformities, muscle weakness, and other health issues.
  • What is KK8123 and how is it administered? KK8123 is a new drug being tested for the treatment of XLH. It is administered subcutaneously, which means it is injected under the skin.
  • What are the main goals of this clinical trial? The main goals of this trial are to assess the safety, tolerability, and effectiveness of KK8123 in adult patients with XLH. The study also aims to understand how the drug behaves in the body and its effects on phosphorus levels in the blood.
  • How long does the clinical trial last? The trial consists of two parts. Part 1 lasts up to 44 weeks, while Part 2 (the optional extension period) lasts up to 52 weeks. The total duration may vary depending on the participant's involvement in both parts.
  • What kind of measurements will be taken during the trial? The trial will measure various factors, including the occurrence of side effects, changes in blood test results, heart function, kidney function, and how the drug moves through and affects the body. Researchers will also closely monitor phosphorus levels in the blood.

Ongoing Clinical Trials on Kk8123

  • Study of KK8123 for Adults with X-linked Hypophosphatemia

    Recruiting

    1 1
    Investigated drugs:
    France Germany Spain

Glossary

  • X-linked Hypophosphatemia (XLH): A rare genetic disorder that affects the body's ability to maintain normal phosphate levels in the blood, leading to bone and muscle problems.
  • Subcutaneous administration: A method of giving medication by injecting it under the skin.
  • Dose escalation: A process in clinical trials where the dose of a drug is gradually increased to find the optimal dosage that balances effectiveness and safety.
  • TEAEs: Treatment-Emergent Adverse Events, which are any unfavorable medical occurrences that happen during the treatment period of a clinical study.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Echocardiogram: A test that uses sound waves to create images of the heart, used to check for heart abnormalities.
  • Renal ultrasound: An imaging test that uses sound waves to create pictures of the kidneys, used to check kidney structure and function.
  • ADA: Anti-Drug Antibodies, which are antibodies produced by the body in response to a medication, potentially affecting its effectiveness or safety.

References

  1. https://clinicaltrials.gov/study/NCT06525636